An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
1 Department of Hematology and Oncology, Meyer Children's Hospital IRCCS, Florence, Italy.
2 Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
3 Nephrology and Dialysis Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
4 Desbres Institute of Epidemiology and Public Health, INSERM, University of Montpellier, Montpellier, France.
5 Department of Health Sciences, University of Florence, Florence, Italy.
6 Internal Medicine Department 2, Institut E3M, French Reference Centre for Histiocytosis, CIMI INSERM-UMRS 1135, Pitié-Salpȇtrière Hospital, Sorbonne University, Assistance Publique-Hôpitaux de Paris, Paris, France.
7 Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France.
8 Department of Pathology, Pitié-Salpêtrière Hospital, Sorbonne University, Assistance Publique-Hôpitaux de Paris, Paris, France.
9 Department of Internal Medicine, Hotel Dieu, Nantes University Hospital, Nantes, France.
10 Department of Internal Medicine, Caen University Hospital, Caen, France.
11 Hematology Clinic, Pitié-Salpêtrière Hospital, Sorbonne University, Assistance Publique-Hôpitaux de Paris, Paris, France.
12 EA4340 BECCOH, Pathology Department, Versailles SQY University, Ambroise Paré Hospital, Assistance Publique-Hôpitaux de Paris, Boulogne, France.
13 Desbrest Institute of Epidemiology and Public Health, INSERM, University of Montpellier, Montpellier, France.
14 Division of Respiratory Medicine, Allergology, and Thoracic Oncology, University Hospital of Montpellier, Montpellier, France.
15 Department of Biomedical, Experimental and Clinical Sciences "Mario Serio," University of Florence, Florence, Italy.
1 Department of Hematology and Oncology, Meyer Children's Hospital IRCCS, Florence, Italy.
2 Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
3 Nephrology and Dialysis Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
4 Desbres Institute of Epidemiology and Public Health, INSERM, University of Montpellier, Montpellier, France.
5 Department of Health Sciences, University of Florence, Florence, Italy.
6 Internal Medicine Department 2, Institut E3M, French Reference Centre for Histiocytosis, CIMI INSERM-UMRS 1135, Pitié-Salpȇtrière Hospital, Sorbonne University, Assistance Publique-Hôpitaux de Paris, Paris, France.
7 Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France.
8 Department of Pathology, Pitié-Salpêtrière Hospital, Sorbonne University, Assistance Publique-Hôpitaux de Paris, Paris, France.
9 Department of Internal Medicine, Hotel Dieu, Nantes University Hospital, Nantes, France.
10 Department of Internal Medicine, Caen University Hospital, Caen, France.
11 Hematology Clinic, Pitié-Salpêtrière Hospital, Sorbonne University, Assistance Publique-Hôpitaux de Paris, Paris, France.
12 EA4340 BECCOH, Pathology Department, Versailles SQY University, Ambroise Paré Hospital, Assistance Publique-Hôpitaux de Paris, Boulogne, France.
13 Desbrest Institute of Epidemiology and Public Health, INSERM, University of Montpellier, Montpellier, France.
14 Division of Respiratory Medicine, Allergology, and Thoracic Oncology, University Hospital of Montpellier, Montpellier, France.
15 Department of Biomedical, Experimental and Clinical Sciences "Mario Serio," University of Florence, Florence, Italy.
This cohort study analyzes the risk of second cancers in a cohort of 515 patients with Erdheim-Chester disease followed up at 2 histiocytosis centers in France and Italy.
Conflict of Interest Disclosures: Dr Cohen-Aubart reported serving as principal investigator of an academic study of cobimetinib in histiocytoses. Dr Tesi reported grants from the Erdheim-Chester Disease Global Alliance during the conduct of the study and grants from GlaxoSmithKline outside the submitted work. No other disclosures were reported.
References
Pegoraro F, Papo M, Maniscalco V, Charlotte F, Haroche J, Vaglio A. Erdheim-Chester disease: a rapidly evolving disease model. Leukemia. 2020;34(11):2840-2857. doi:10.1038/s41375-020-0944-4
-
DOI
-
PubMed
Cohen Aubart F, Roos-Weil D, Armand M, et al. . High frequency of clonal hematopoiesis in Erdheim-Chester disease. Blood. 2021;137(4):485-492. doi:10.1182/blood.2020005101
-
DOI
-
PMC
-
PubMed
Papo M, Diamond EL, Cohen-Aubart F, et al. . High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. Blood. 2017;130(8):1007-1013. doi:10.1182/blood-2017-01-761718
-
DOI
-
PMC
-
PubMed
Pegoraro F, Papo M, Cohen-Aubart F, et al. . Long-term outcome and prognosis of mixed histiocytosis (Erdheim-Chester disease and Langerhans cell histiocytosis). EClinicalMedicine. 2024;73:102658. doi:10.1016/j.eclinm.2024.102658
-
DOI
-
PMC
-
PubMed
Acosta-Medina AA, Kemps PG, Zondag TCE, et al. . BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis. Blood. 2023;142(18):1570-1575. doi:10.1182/blood.2023021212
-
DOI
-
PMC
-
PubMed
